Immunotherapy of inflammatory diseases, 2005.
The management of inflammatory diseases has entered a new era, marked by the rise of new immunotherapy strategies. This concept was born thanks to the increasingly precise comprehension of their mechanism and the development of new therapeutic biological tools; progress that is probably as important as the discovery of steroids half a century ago. The use of biotherapies is now widespread, and, to date, approximately 1 million patients in the world have been treated with anti-TNF. Large-scale immunotherapy has requirements of which one should be aware. It is essential that users acquire a very high level of qualification. For handling biotherapies well, it is necessary to know the characteristics of biological tools (monoclonal antibodies, soluble receptors); in particular, their mode of action and their pharmacokinetic and pharmacodynamic properties. To optimise the use of these molecules, it is essential to know not only their characteristics but also the individual factors which make it possible to predict effectiveness and tolerance. Various approaches will allow a true 'pharmacoprediction' in order to determine 'the right drug for the right patient'. Thus, if this objective is achieved, it might be possible, in the immediate future, to propose à la carte therapeutic strategies, which avoid the most severe effects associated with the successive use of empirical immunosuppressor treatments. Lastly, it is essential for experts to identify new therapeutic strategies. This can be done only by mastering the most relevant advances of immunopathology, beyond the experimental models which are often difficult to extrapolate in humans. Thanks to this, original strategies, such as the modulation of costimulation pathways or the inhibition of mast cells, can be explored. This supplement is the synthesis of a conference on immunotherapies which gathered biologists and doctors of different horizons, all experts in biotherapies. The objective of this meeting can be summarised in two keywords: to understand and anticipate. These two concepts are essential for a specialist in immunomodulatory therapeutics. Thus, we hope that the information, brought by acknowledged experts, will enable you to enhance your knowledge on immunotherapies for the benefit of patients. Thank you for having allowed us to discover with enthusiasm these original aspects of modern immunotherapies of inflammatory diseases. See you soon at the 2006 conference.
Sibilia
Jean
J
CHU Hautepierre Universite Louis Pasteur 1, Service de Rhumatologie, Avenue Moliere, 67098 Strasbourg, France.
Griscelli
Claude
C
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction; D013678:Technology, Pharmaceutical
D000911:Antibodies, Monoclonal; D016207:Cytokines; D011993:Recombinant Fusion Proteins